Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
By analyzing the complex ways in which the immune system interacts with cancercells, we can split women with breast cancer into two groups, who ...
Novel Test Links Immune Hotspots to Improved Breast Cancer Prognosis - Immuno-Oncology News
Manipulating cells' shapes could treat breast cancer - Medical Xpress
New breast cancer test indicates better survival - Spire Healthcare
The immune system is not a single entity like a bicep. ... such as AIDs or cancer) individual's immune system is working optimally, no boosting possible ...
... a therapy that can jumpstart an immune attack on specific cancer cells with new therapies that are exposing cancer to immune system assaults.
Bristol-Myers, Bavarian Nordic Ink Prostate-Cancer Deal - Wall Street Journal
This requires a separate test for each cancer type. ... Ordinarily, a mouse's immune system would attack any injected human cell, cancerous or not.
Immune system function, cancer. Stress hinders a person's immune system and increases inflammation in the body — leaving them vulnerable to ...
Instead of poisoning a tumor or destroying it with radiation, Dr. Allison has pioneered ways to unleash the immune system to destroy a cancer.".
(Reuters) - U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most ...
A new study in the journal Science Translational Medicine proposes that adding oxygen to immunotherapy cancer treatments can weaken a tumor's ...
Extra Oxygen Could Help Fight Cancer, Study Suggests - NBC Bay Area
Could Oxygen Make Cancer Therapy Work Better? - NBCNews.com
Mouse study suggests high doses of oxygen can lower cancer's defense against immune cells - Minneapolis Star Tribune
Gene Alterations in Melanoma May Predict Immunotherapy Outcomes ... according to a study published in Cancer Immunology Research, a journal of ...
This, in turn, could improve cancer immunotherapy and shrink tumors by unleashing anti-tumor T lymphocytes and natural killer cells.
... in radiation biology, demonstrating the efficacy of combining radiotherapy with immunotherapy to control cancer cell growth in solid tumors.
"Cancer immunotherapy continues to be one of the most exciting approaches to treating cancer, but also one that is rapidly evolving. Application of ...
SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, ...
CORRECTING and REPLACING OncoSec Medical to Present at Prominent Scientific and ... - Business Wire (press release)
Vaccine-based cancer immunotherapies currently under development aim to direct the patient's immune system against tumor specific antigens.
A regular update on what's new in cancer research from our friends at Clinical Oncology News. Read more
Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) coupled with aggressive surgery demonstrates high resection rates in ...
Classifying pancreatic cancer into four subtypes based on whole genome sequencing could help improve the specificity of existing treatments.
This potential blockbuster drug is also approved in the U.S. and EU for metastatic breast cancer and advanced pancreatic cancer. The drug was ...
Then on February 17 and 18, the FDA granted Reolysin a designation for the treatments of pancreatic cancer and colorectal cancer. Shares of ...
ORLANDO, Florida ― Small cell bladder carcinoma (SCBC) is a rare, aggressive subtype of bladder cancer that is generally diagnosed at an ...
Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary ...
More than 70% of patients with high-risk non-muscle invasive bladder cancer had a complete response lasting 3 months or longer after receiving ...
... and End Results-Medicare data set from 1992-2009, we identified 28,854 men with prostate cancer, 5462 patients with bladder cancer, and 14,379 ...
Standardized analysis of complications after robot-assisted radical cystectomy: Korea University ...
... prospectively reviewed a maintained institutional database of 52 patients who underwent RARC to manage bladder cancer and were followed up in ...
It could be a simple approach to making cancer therapies work better, .... They are used to treat patients with pancreatic cancer and other serious ...
As an example, in September 2014, the company announced Phase II data in pancreatic cancer, an indication where they have subsequently ...
We have fine-mapped one of these loci (Region 2) in pancreatic, testicular and lung cancer to a set of seven highly correlated SNPs. Through genomic ...
Ipilimumab Doubled 5-Year Survival in Advanced Melanoma
Advanced melanoma patients who received front-line ipilimumab/dacarbazine had double the 5-year survival rate compared with those on dacarbazine alone.
Advanced melanoma patients who received front-line ipilimumab/dacarbazine had double the 5-year survival rate compared with those on dacarbazine alone.
Lung-RADS Reduces False Positives, Sensitivity of Lung Screening
A classification system known as Lung-RADS reduced false positive rates but also decreased the sensitivity of low-dose CT screening compared with NLST standards.
A classification system known as Lung-RADS reduced false positive rates but also decreased the sensitivity of low-dose CT screening compared with NLST standards.
Sentinel Lymph Node Biopsy Indicated in Thick Melanomas
A single-institution study found that patients with melanomas of 4 mm thickness who had a negative sentinel lymph node biopsy had significantly prolonged survival.
A single-institution study found that patients with melanomas of 4 mm thickness who had a negative sentinel lymph node biopsy had significantly prolonged survival.
Patient Factors Linked With Ibrutinib Discontinuation
Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.
Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.
Hormone Therapy Adherence in Breast Cancer Linked to Race, Income
Economic factors, including household income, and racial disparities both play a role in the adherence to hormonal therapy in breast cancer patients.
Economic factors, including household income, and racial disparities both play a role in the adherence to hormonal therapy in breast cancer patients.
Fewer Lung Cancer Patients Eligible for Screening
A retrospective analysis suggested that a declining proportion of patients with lung cancer would meet the criteria for undergoing low-dose CT screening.
A retrospective analysis suggested that a declining proportion of patients with lung cancer would meet the criteria for undergoing low-dose CT screening.
High Cost, Minimal Benefit for Bevacizumab in Metastatic CRC
Bevacizumab as first-line therapy for metastatic CRC equated to an incremental cost-effectiveness ratio of more than half a million dollars per QALY.
Bevacizumab as first-line therapy for metastatic CRC equated to an incremental cost-effectiveness ratio of more than half a million dollars per QALY.
FDA Approves Panobinostat for Multiple Myeloma
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
MBCC 2015
First-Line Option Clear in Sequencing of HER2-Positive Breast Cancer Treatments
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
Pain Control an Important Aspect of Breast Cancer Treatment
As part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.
As part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.
MRI Screening for Breast Cancer
As part of our MBCC coverage we discuss MRI screening for breast cancer in patients who carry a BRCA mutation or have a first-degree relative who is a BRCA carrier.
As part of our MBCC coverage we discuss MRI screening for breast cancer in patients who carry a BRCA mutation or have a first-degree relative who is a BRCA carrier.
Modern Breast Cancer Staging Should Include Tumor Biology
According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.
According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.
Exposure to In Utero Chemotherapy Did Not Affect Children's Development, Behavior
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
Majority of Metaplastic Breast Cancers May Be Targetable
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Eribulin Dose-Modification May Allow for Better Outcomes
Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.
Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.
Breast Cancer Not Overdiagnosed by Mammography
The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.
The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.
Enough is Enough: Screening Mammography Saves Lives
At MBCC, one presenter made the argument for screening mammography for all women starting at the age of 40, despite the controversy surrounding the topic.
At MBCC, one presenter made the argument for screening mammography for all women starting at the age of 40, despite the controversy surrounding the topic.
HR-Positive Breast Cancer Patients May Have More Anxiety
Women with hormone receptor-positive breast cancer may be more scared, anxious, or concerned about treatment-related adverse events and cancer symptoms.
Women with hormone receptor-positive breast cancer may be more scared, anxious, or concerned about treatment-related adverse events and cancer symptoms.
Physician Age May Affect Beliefs About Breast Cancer Screening
A physician's age may have an effect on his or her opinions about the effectiveness of breast cancer screening methods, including self-exam and mammography.
A physician's age may have an effect on his or her opinions about the effectiveness of breast cancer screening methods, including self-exam and mammography.
Science Daily Cancer News
A guideline has been issued that outlines the use of 3-D computed tomography (CT)-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects.
Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report. The review identified suicide in these patients as a public health dilemma that needs physician awareness, particularly in patients who are older, male, and have aggressive disease.
The more copies of a genome a cell holds, the more adaptable those cells are, scientists have discovered. This may have implications for cancer's evolution and adaptation.
Researchers have developed and characterized a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. The investigators performed a series of studies utilizing high-content analysis, which quantifies changes in living cells in response to a drug treatment. The lab focused on the effects of a patented small molecule, known as UCD38B, on four different human glioma cell lines.
Rutgers Cancer Institute of New Jersey is offering a clinical trial examining the investigational treatment known as ONC201 in patients with solid tumors whose cancer no longer responds to standard therapy. Prior research on the study drug suggests that it may be capable of turning off proteins that maintain tumor growth and and may help kill cancer cells while sparing normal ones.
More than any other debate about overdiagnosis, the discussion of breast cancer has spilt from the pages of the specialist medical press into the public domain, argues a public health expert, stating that changing screening policy "should be based on demonstrated ability to achieve equivalent benefit to harm ratios and not on the assumption that increased detection will achieve a net benefit."
People have highly variable views on how much overdetection is acceptable in cancer screening, finds a UK survey.
Two biomarkers have been discovered by researchers that may improve oncologists’ ability to predict which patients’ prostate cancer will recur after surgery, long before the development of visible cancer elsewhere in the body.
Tambahkan Komentar